Health activist, scholar, award-winning journalist, and cancer survivor Sharon Batt investigates the relationship between patient advocacy groups and the pharmaceutical industry as well as the contentious role of pharma funding. Over the past several decades, a gradual reduction in state funding has pressured patient groups into forming private-sector partnerships. This analysis of Canadas breast cancer movement from 1990 to 2010 shows that the resulting power imbalance undermined the groups ability to put patients interests ahead of those of the funders. A movement that once encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry.
Preface
Introduction: The Secret War among Patient Groups
Part 1: Canadas Health Care System Transformed Neoliberalism and the Erosion of the Welfare State
1 Canadas Health Policy Landscape
2 Health Advocacy Organizations in Canada
Part 2: From Grassroots to Contestation to Partnership The Breast Cancer Movement and Big Pharma
3 Beginnings of the Breast Cancer Movement
4 Advocacy Redefined
5 The Movement Fractures over Pharma Funding
6 Pharma Funding as the New Norm
7 Advocacy Groups and the Continuing Struggle over the Pharma-Funding Question
Conclusion: The Fight for Medicines Soul
Appendix: Organizations and Their Members
Notes
Index